Cerebrovascular Diseases Treatment Market By Type of Stroke (Ischemic and Hemorrhagic), By Treatment (Medical and Surgical Procedure), By End User (Hospitals, Surgical Clinics, and Research Institutes) - Global Industry Share, Growth, Competitive Analysis, And Forecast, 2022-2028
The global cerebrovascular disease treatment market is expected to grow at a considerable CAGR of 5.9% during the forecast period. The major factors that are augmenting the growth of the cerebrovascular disease treatment market are advancement in technology and increasing prevalence of strokes. Furthermore, expansion and spending on healthcare infrastructure in the emerging economies, favorable medical reimbursements are also estimated to be the major factors that are contributing significantly towards the growth of the market. Above 85.0% of the strokes are of ischemic stroke which makes it most commonly caused due to less blood supply to the brain. In addition to this, several government organizations play an important role in the growth of the market. For instance, in 2016, the Society of Vascular and Interventional Neurology (SVIN) started a health campaign of Mission Thrombectomy 2020 to accelerate the access of stroke treatment globally by doubling the normal rate of treatment by 2020. The stroke diseases require early treatment as it is can be life-threatening due to some delay in treatment.
However, the lack of awareness among the people, the absence of skilled neurosurgeons and diagnostic centers, and the high cost of cerebrovascular treatment are some of the restraints that can challenge the growth of the market in the forecast period. Conversely, the high growth rate in healthcare infrastructure and the increasing number of research in the field are the opportunities that are expected to fuel the cerebrovascular diseases treatment market.
The market is segmented on the basis of type of stroke, treatment, and end-user. By type of stroke, the market is segmented into ischemic and Hemorrhagic. The ischemic stroke treatment segment holds a significant market share during the forecast period. Ischemic stroke is driven by the high patient pool, growth in prevalence of stroke, and rise in R&D facilities. The ischemic stroke treatment major players include Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, and Medtronic. Moreover, based on the treatment segment, the market is segmented into medication and surgical procedures. Further, based on the end-user segment, the market is segmented into hospitals, surgical clinics, and research institutes.
Global Cerebrovascular disease treatment Market Share by type of stroke, 2020 (%)
Global Cerebrovascular disease treatment Market Share by type of stroke
The global cerebrovascular disease treatment market is analyzed based on the geographical regions into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to be one of the leading regions in the global cerebrovascular disease treatment market. Increase in R&D investments by the manufacturers, the rising level of hypertension and migraine, advancement and availability of technologies, and government initiatives are the major factor driving the growth of the market in this region. The US is estimated to have the highest share of the market in this region due to the high penetration of patented drugs in the country.
Global Cerebrovascular disease treatment Market Growth, by Region 2022-2028
Global Cerebrovascular disease treatment Market Growth, by Region
Asia Pacific is estimated to among the fastest-growing region during the forecast period. The factors promoting the growth of the market in the region include increasing awareness related to heart diseases, increasing disposable income, and increasing incidences related to heart disease due to unhealthy lifestyles. Moreover, favorable government policies to expand healthcare infrastructure in the region such as in China, India, and ASEAN and growth in medical tourism is also driving the market growth.
Market Players Outlook
Key players of the cerebrovascular disease treatment market are Abbott Laboratories, Pfizer Inc., Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Penumbra, Inc., and Johnson & Johnson Services, Inc. In order to survive in the market, these players adopt different marketing strategies such as mergers, acquisitions, product launches, and geographical expansion so on. For Instance, in October 2020, Bayer AG acquired Asklepios BioPharmaceutical to broaden its platform and potential for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cerebrovascular disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
5.2. Global Cerebrovascular Disease Treatment Market, By Treatment
5.2.2. Surgical Procedure
5.3. Global Cerebrovascular Disease Treatment Market, By End User
5.3.2. Surgical Clinics
5.3.3. Research Institutions
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7.2. Amgen Inc.
7.3. AstraZeneca plc
7.4. Bayer AG
7.5. Boehringer Ingelheim International GmbH
7.6. Bristol-Myers Squibb Co.
7.7. Daiichi Sankyo Co. Ltd.
7.8. F. Hoffmann-La Roche Ltd.
7.9. Genentech, Inc.
7.10. Johnson & Johnson Services, Inc.
7.11. Medtronic plc
7.12. Merck & Co., Inc.
7.13. Penumbra, Inc.
7.14. Pfizer Inc.
7.15. Sangamo Therapeutics, Inc.
7.16. Sanofi SA
7.17. Siemens Healthineers AG
7.18. Sihuan Pharmaceutical Holdings Group Ltd.
7.19. Takeda Pharmaceutical Co. Ltd.
7.20. United Therapeutics Corp.
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Johnson & Johnson Services, Inc.
- Medtronic plc
- Merck & Co., Inc.
- Penumbra, Inc.
- Pfizer Inc.
- Sangamo Therapeutics, Inc.
- Sanofi SA
- Siemens Healthineers AG
- Sihuan Pharmaceutical Holdings Group Ltd.
- Takeda Pharmaceutical Co. Ltd.
- United Therapeutics Corp.